US FDA approves Takeda’s Livtencity to treat people with post-transplant Cytomegalovirus infection

In the phase-III Solstice study, more than twice the proportion of adult transplant recipients with refractory or resistant (R/R) CMV infection/disease achieved confirmed CMV DNA level